Cargando…
Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152]
Autores principales: | Koga, Satoko, Onishi, Hideya, Masuda, Shogo, Fujimura, Akiko, Ichimiya, Shu, Nakayama, Kazunori, Imaizumi, Akira, Nishiyama, Kenichi, Kojima, Masayuki, Miyoshi, Kei, Nakamura, Katsuya, Umebayashi, Masayo, Morisaki, Takashi, Nakamurab, Masafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777136/ https://www.ncbi.nlm.nih.gov/pubmed/35042060 http://dx.doi.org/10.1016/j.tranon.2022.101344 |
Ejemplares similares
-
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor
por: Koga, Satoko, et al.
Publicado: (2021) -
C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions
por: Nagao, Shinjiro, et al.
Publicado: (2023) -
GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer
por: Ichimiya, Shu, et al.
Publicado: (2021) -
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
por: Morisaki, Shinji, et al.
Publicado: (2023) -
FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients
por: Saeki, Kiyoshi, et al.
Publicado: (2020)